AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma

Figure 2 Receiver operating characteristic curve analysis of the predictive performance of the AADN score in the training cohort and validation cohort. A: Receiver operating characteristic (ROC) curve analysis of the predictive performance of the AADN score in the training cohort; B: ROC curve analysis of the predictive performance of the AADN score in the validation cohort; C: Calibration curve of the AADN score for predicting 3-year survival; D: ROC curve was used to compare the diagnostic efficacy of AADN score, hepatic arterial infusion chemotherapy score and albumin-bilirubin score. ROC: Receiver operating characteristic; NLR: Neutrophil to lymphocyte ratio; AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; DBIL: Direct bilirubin; AUC: Area under the curve; CI: Confidence interval; HAP: Hepatic arterial infusion chemotherapy; ALBI: Albumin-bilirubin.